CoChat

Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells

Open access

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

We report a defined method for differentiating human pluripotent stem cells to brain endothelial cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.1701679

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic of BMEC differentiation protocol. (A) Singularized hPSCs are seeded on six-well plates coated with Matrigel, vitronectin, or Synthemax and expanded for 3 days in mTeSR1. Differentiation to primitive streak is initiated by 24-hour treatment with 6 μM CHIR99021 in DeSR1. Cells progress to intermediate mesoderm and endothelial progenitors during culture in serum-free defined DeSR2 medium. At day 6, BMEC specification is induced by culture in hESFM supplemented with 2% B27, 10 μM RA, and bFGF (20 ng/ml) (hECSR1) for 2 days. After replating on Matrigel or fibronectin/collagen IV substrates, BMECs are obtained. (B to D) The pluripotent state of expanded hPSCs was verified before differentiation by immunofluorescence for OCT4 (B), NANOG (C), and TRA-1-60 (D). DAPI, 4′,6-diamidino-2-phenylindole. (E and F) The expression of the primitive streak marker brachyury was assessed by immunofluorescence (E) and flow cytometry (F) 24 hours after CHIR99021 treatment. IgG, immunoglobulin G; FSC, forward scatter. (G and H) On day 4 of differentiation, the expression of the intermediate mesoderm marker PAX2 was quantified. (I and J) On day 5, the expression of the endothelial progenitor marker VEGFR2 was analyzed. Scale bars, 100 μm.
Fig. 1 Schematic of BMEC differentiation protocol. (A) Singularized hPSCs are seeded on six-well plates coated with Matrigel, vitronectin, or Synthemax and expanded for 3 days in mTeSR1. Differentiation to primitive streak is initiated by 24-hour treatment with 6 μM CHIR99021 in DeSR1. Cells progress to intermediate mesoderm and endothelial progenitors during culture in serum-free defined DeSR2 medium. At day 6, BMEC specification is induced by culture in hESFM supplemented with 2% B27, 10 μM RA, and bFGF (20 ng/ml) (hECSR1) for 2 days. After replating on Matrigel or fibronectin/collagen IV substrates, BMECs are obtained. (B to D) The pluripotent state of expanded hPSCs was verified before differentiation by immunofluorescence for OCT4 (B), NANOG (C), and TRA-1-60 (D). DAPI, 4′,6-diamidino-2-phenylindole. (E and F) The expression of the primitive streak marker brachyury was assessed by immunofluorescence (E) and flow cytometry (F) 24 hours after CHIR99021 treatment. IgG, immunoglobulin G; FSC, forward scatter. (G and H) On day 4 of differentiation, the expression of the intermediate mesoderm marker PAX2 was quantified. (I and J) On day 5, the expression of the endothelial progenitor marker VEGFR2 was analyzed. Scale bars, 100 μm.CC BY-NC · PubMed Central
Fig. 2 hPSC-derived BMECs express key BMEC proteins and have gene expression profiles similar to those of primary human BMECs. (A to I) At day 10, BMECs differentiated as shown in Fig. 1A were characterized by immunocytofluorescence (A) and flow cytometry (B to I) for key endothelial and BMEC markers. Scale bars, 100 μm. (J) Hierarchical clustering of whole transcripts counted by RNA sequencing was plotted using GENE-E. Hierarchical clustering analysis was performed on log2-transformed gene counts of RNA sequencing expression data of undifferentiated hPSCs (76–78); hPSC-derived endoderm (Endo) (76), ectoderm (Ecto) (77), and mesoderm (Mes) (78); BMECs differentiated under defined conditions as illustrated in Fig. 1A (D-BMEC1, D-BMEC2, and D-BMEC3: IMR90-4–derived BMECs at day 10 generated from three independent differentiations); BMECs differentiated in UM (UM-BMECs); and human primary BMECs (hBMECs). Distances were computed using one minus Pearson correlation with average linkage. (K) A set of 506 tight junction and transporter genes (table S1) was used to investigate gene expression similarity between primary human BMECs, hPSC-derived BMECs differentiated under defined conditions, and hPSC-derived BMECs differentiated in UM (32). The gene set included 20 tight junction–related genes (1, 53–56), all 25 CLDN genes, all 407 solute carrier (SLC) transporters, and all 53 ATP-binding cassette (ABC) transporters. CLDN, SLC, and ABC genes were included without previous knowledge of BBB association. A threshold of >1 fragment per kilobase million (FPKM) was used to define expressed versus nonexpressed transcripts.
Fig. 2 hPSC-derived BMECs express key BMEC proteins and have gene expression profiles similar to those of primary human BMECs. (A to I) At day 10, BMECs differentiated as shown in Fig. 1A were characterized by immunocytofluorescence (A) and flow cytometry (B to I) for key endothelial and BMEC markers. Scale bars, 100 μm. (J) Hierarchical clustering of whole transcripts counted by RNA sequencing was plotted using GENE-E. Hierarchical clustering analysis was performed on log2-transformed gene counts of RNA sequencing expression data of undifferentiated hPSCs (76–78); hPSC-derived endoderm (Endo) (76), ectoderm (Ecto) (77), and mesoderm (Mes) (78); BMECs differentiated under defined conditions as illustrated in Fig. 1A (D-BMEC1, D-BMEC2, and D-BMEC3: IMR90-4–derived BMECs at day 10 generated from three independent differentiations); BMECs differentiated in UM (UM-BMECs); and human primary BMECs (hBMECs). Distances were computed using one minus Pearson correlation with average linkage. (K) A set of 506 tight junction and transporter genes (table S1) was used to investigate gene expression similarity between primary human BMECs, hPSC-derived BMECs differentiated under defined conditions, and hPSC-derived BMECs differentiated in UM (32). The gene set included 20 tight junction–related genes (1, 53–56), all 25 CLDN genes, all 407 solute carrier (SLC) transporters, and all 53 ATP-binding cassette (ABC) transporters. CLDN, SLC, and ABC genes were included without previous knowledge of BBB association. A threshold of >1 fragment per kilobase million (FPKM) was used to define expressed versus nonexpressed transcripts.CC BY-NC · PubMed Central
Fig. 3 hPSC-derived BMECs exhibit key BBB phenotypes. hPSC-derived BMECs were differentiated as illustrated in Fig. 1A. (A) Immunofluorescence images of vWF (red) and DAPI staining (blue) in hPSC-derived BMECs at day 10. (B) hPSC-derived BMECs were dissociated with Accutase and replated at 1 × 105 cells/cm2 on Matrigel. Images were taken after 24 hours in hECSR2 with VEGF (50 ng/ml). (C) hPSC-derived BMECs at day 10 were analyzed with an LDL Uptake Assay kit. LDL is shown in red on a merged bright-field image. (D to F) ICAM-1 induction in hPSC-derived BMECs. hPSC-derived BMECs at day 10 were treated with TNF-α (10 ng/ml) for 16 hours. Immunofluorescence images for ICAM-1 were acquired before (D) and after (E) TNF-α treatment. (F) Cells were dissociated with Accutase, and ICAM-1 expression was quantified by flow cytometry before and after TNF-α treatment. Efflux transporter activities were measured by the intracellular accumulation of (G) rhodamine 123, (H) Hoechst, and (I) DCFDA, substrates for Pgp, BCRP, and MRP, respectively. CsA, Ko143, and MK571 were used as specific inhibitors of Pgp, BCRP, and MRP, respectively. (J) The polarization of Pgp was measured by rhodamine 123 transport across the BMEC monolayer from the apical to basolateral side (A-B) and vice versa (B-A). Inhibitor-treated samples were independently normalized to each respective non–inhibitor-treated control sample. (K) TEER was measured in hPSC-derived BMECs cocultured with astrocytes, neurons, and pericytes. Data were collected from three independent replicates and are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars, 100 μm.
Fig. 3 hPSC-derived BMECs exhibit key BBB phenotypes. hPSC-derived BMECs were differentiated as illustrated in Fig. 1A. (A) Immunofluorescence images of vWF (red) and DAPI staining (blue) in hPSC-derived BMECs at day 10. (B) hPSC-derived BMECs were dissociated with Accutase and replated at 1 × 105 cells/cm2 on Matrigel. Images were taken after 24 hours in hECSR2 with VEGF (50 ng/ml). (C) hPSC-derived BMECs at day 10 were analyzed with an LDL Uptake Assay kit. LDL is shown in red on a merged bright-field image. (D to F) ICAM-1 induction in hPSC-derived BMECs. hPSC-derived BMECs at day 10 were treated with TNF-α (10 ng/ml) for 16 hours. Immunofluorescence images for ICAM-1 were acquired before (D) and after (E) TNF-α treatment. (F) Cells were dissociated with Accutase, and ICAM-1 expression was quantified by flow cytometry before and after TNF-α treatment. Efflux transporter activities were measured by the intracellular accumulation of (G) rhodamine 123, (H) Hoechst, and (I) DCFDA, substrates for Pgp, BCRP, and MRP, respectively. CsA, Ko143, and MK571 were used as specific inhibitors of Pgp, BCRP, and MRP, respectively. (J) The polarization of Pgp was measured by rhodamine 123 transport across the BMEC monolayer from the apical to basolateral side (A-B) and vice versa (B-A). Inhibitor-treated samples were independently normalized to each respective non–inhibitor-treated control sample. (K) TEER was measured in hPSC-derived BMECs cocultured with astrocytes, neurons, and pericytes. Data were collected from three independent replicates and are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars, 100 μm.CC BY-NC · PubMed Central
Fig. 4 Initial seeding density is critical for BMEC differentiation. (A) hPSCs were seeded at the indicated densities (from 8800 to 140,000 cells/cm2) and differentiated to BMECs, as illustrated in Fig. 1A. TEER was measured 2 days after replating on Transwell membranes at 106 cells/cm2. (B) TEERs of hPSC-derived BMECs were measured daily for 7 days after replating on Transwell membranes. Data were collected from three independent replicates and are means ± SEM. ***P < 0.001. (C to E) The percentage of claudin-5–positive cells and expression levels of claudin-5 were quantified by flow cytometry at day 8 for cells differentiated at the indicated seeding density (cells/cm2). (F) The localization of claudin-5 in cells differentiated at different seeding densities was investigated by immunofluorescence. White arrows indicate sample areas lacking claudin-5 expression, and red arrows indicate discontinuous claudin-5. (G to I) The percentage of occludin-positive cells and expression levels of occludin were quantified by flow cytometry at day 8 for cells differentiated at the indicated seeding density (cells/cm2). (J) The localization of occludin in cells differentiated at different seeding densities was investigated by immunofluorescence. White arrows indicate sample areas lacking occludin expression, and red arrows indicate discontinuous occludin. Flow cytometry plots are representative of three independent experiments. Insets indicate the mean percentage of cells in the immunopositive gated region ± SEM. Scale bars, 100 μm.
Fig. 4 Initial seeding density is critical for BMEC differentiation. (A) hPSCs were seeded at the indicated densities (from 8800 to 140,000 cells/cm2) and differentiated to BMECs, as illustrated in Fig. 1A. TEER was measured 2 days after replating on Transwell membranes at 106 cells/cm2. (B) TEERs of hPSC-derived BMECs were measured daily for 7 days after replating on Transwell membranes. Data were collected from three independent replicates and are means ± SEM. ***P < 0.001. (C to E) The percentage of claudin-5–positive cells and expression levels of claudin-5 were quantified by flow cytometry at day 8 for cells differentiated at the indicated seeding density (cells/cm2). (F) The localization of claudin-5 in cells differentiated at different seeding densities was investigated by immunofluorescence. White arrows indicate sample areas lacking claudin-5 expression, and red arrows indicate discontinuous claudin-5. (G to I) The percentage of occludin-positive cells and expression levels of occludin were quantified by flow cytometry at day 8 for cells differentiated at the indicated seeding density (cells/cm2). (J) The localization of occludin in cells differentiated at different seeding densities was investigated by immunofluorescence. White arrows indicate sample areas lacking occludin expression, and red arrows indicate discontinuous occludin. Flow cytometry plots are representative of three independent experiments. Insets indicate the mean percentage of cells in the immunopositive gated region ± SEM. Scale bars, 100 μm.CC BY-NC · PubMed Central
Fig. 5 RA induces acquisition of key BMEC phenotypes in EC progenitors. BMECs were differentiated as shown in Fig. 1A in the presence or absence of RA, as indicated. (A) At day 8, the expression of tight junction and transporter genes was assessed by qPCR. (B) Flow cytometry for CD31 expression was performed at days 6 (D6) and 8 (D8). (C) Pgp expression was quantified by flow cytometry at day 10. At day 6, the medium was switched to hESFM containing or lacking RA, as indicated. (D) At day 8, cells were replated onto Matrigel-coated Transwell membranes at 106 cells/cm2 in the presence or absence of 10 μM Y-27632. TEER was measured at day 10, 2 days after replating. (E to G) Occludin (E and G) and ZO-1 (F and G) expression and localization were assessed by flow cytometry and immunofluorescence at day 10. Red arrows indicate discontinuous occludin or ZO-1 localization. (H and I) At day 10, the expression levels of claudin-5 in BMECs differentiated in the presence or absence of RA were assessed by flow cytometry. (J) The localization and expression of claudin-5 of cells differentiated in the absence of RA were determined via immunofluorescence (white arrows indicate cells lacking claudin-5, and red arrows indicate discontinuous claudin-5). Images, bar graphs, and flow cytometry plots are representative of three independent experiments. Data from three independent replicates are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Insets denote either percentage of positively labeled cells or percentage increase in marker expression upon RA treatment. Scale bars, 100 μm.
Fig. 5 RA induces acquisition of key BMEC phenotypes in EC progenitors. BMECs were differentiated as shown in Fig. 1A in the presence or absence of RA, as indicated. (A) At day 8, the expression of tight junction and transporter genes was assessed by qPCR. (B) Flow cytometry for CD31 expression was performed at days 6 (D6) and 8 (D8). (C) Pgp expression was quantified by flow cytometry at day 10. At day 6, the medium was switched to hESFM containing or lacking RA, as indicated. (D) At day 8, cells were replated onto Matrigel-coated Transwell membranes at 106 cells/cm2 in the presence or absence of 10 μM Y-27632. TEER was measured at day 10, 2 days after replating. (E to G) Occludin (E and G) and ZO-1 (F and G) expression and localization were assessed by flow cytometry and immunofluorescence at day 10. Red arrows indicate discontinuous occludin or ZO-1 localization. (H and I) At day 10, the expression levels of claudin-5 in BMECs differentiated in the presence or absence of RA were assessed by flow cytometry. (J) The localization and expression of claudin-5 of cells differentiated in the absence of RA were determined via immunofluorescence (white arrows indicate cells lacking claudin-5, and red arrows indicate discontinuous claudin-5). Images, bar graphs, and flow cytometry plots are representative of three independent experiments. Data from three independent replicates are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Insets denote either percentage of positively labeled cells or percentage increase in marker expression upon RA treatment. Scale bars, 100 μm.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 254

Metadata

Authors
Qian, T., Maguire, S. E., Canfield, S. G., Bao, X., Olson, W. R., Shusta, E. V., & Palecek, S. P.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
  • Shusta, Eric V.
  • Palecek, Sean P.
Venue
Science Advances
Published
2017-11-03
Volume
3
Issue
11
Pages
e1701679-e1701679
ISSN
2375-2548 (ISSN-L)
OpenAlex
W2767330810
Cited by
254
References
79
Citations by year
2026: 20 · 2025: 21 · 2024: 34 · 2023: 24 · 2022: 48 · 2021: 36 · 2020: 31 · 2019: 28 · 2018: 12
FWCI
9.67
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (award324272, R21 NS085351, award324273, R01 NS083699)
  • National Institute of Biomedical Imaging and Bioengineering (award324271, R01 EB007534)
  • Takeda Pharmaceuticals U.S.A. (award324274)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
human pluripotent stem cells, blood-brain barrier endothelial cells, directed differentiation, in vitro BBB model, brain disorders, treatment development
MeSH terms
Blood-Brain Barrier, Cell Differentiation, Humans, Phenotype, Transcription Factors, Electric Impedance, Coculture Techniques, Cell Lineage, Pluripotent Stem Cells, Endothelial Cells, Transcriptome, Claudin-5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.